文献速递肝病消化道肿瘤与早癌

靶向SOAT1重塑脂肪酸代谢并揭示肝细胞癌免疫脆弱性

Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2025-10-09

该研究探讨了甾醇O-酰基转移酶1(SOAT1)在肝细胞癌(HCC)中的分子机制及免疫调节作用。通过遗传学和药物抑制SOAT1,在细胞系、患者来源类器官和小鼠模型中研究发现,SOAT1缺失破坏脂质稳态,导致饱和脂肪酸、活性氧和内质网应激积累,激活NF-κB,招募CD11c+抗原提呈细胞和细胞毒性CD8+T细胞,并减少肿瘤负荷;SOAT1抑制与PD-1阻断联用具有协同抗肿瘤效应。

要点

  • SOAT1在HCC肿瘤中显著上调,与致瘤性和免疫逃逸相关。
  • SOAT1缺失破坏脂质稳态,激活NF-κB并招募CD8+T细胞。
  • SOAT1抑制与PD-1阻断联用具有协同抗肿瘤效应。

核心结论

  • SOAT1是HCC的代谢脆弱点和免疫调节因子,抑制SOAT1可破坏促瘤代谢并增强免疫激活,与PD-1阻断联用有协同抗肿瘤潜力。

研究设计与样本

  • 研究使用遗传学和药物抑制SOAT1,在细胞系、患者来源类器官和小鼠模型中进行,采用共培养系统、流式细胞术和免疫组化评估肿瘤-免疫相互作用,并行多组学分析。

主要发现

  • SOAT1在HCC肿瘤中显著上调,与致瘤性增加和免疫逃逸特征相关。
  • SOAT1缺失破坏脂质稳态,导致饱和脂肪酸、活性氧和内质网应激积累,随后激活NF-κB。
  • 该信号触发促炎细胞因子、黏附分子产生,并招募CD11c+抗原提呈细胞和细胞毒性CD8+T细胞进入肿瘤。
  • SOAT1敲除减少肿瘤负荷,SOAT1抑制与PD-1阻断联用显示协同抗肿瘤效应。

临床怎么用

  • SOAT1抑制可能作为HCC治疗策略,与PD-1阻断联用有望改善HCC免疫治疗结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The development of hepatocellular carcinoma (HCC) is intricately linked to metabolic processes and immune evasion strategies. As an emerging metabolic vulnerability in HCC, the detailed molecular mechanisms of sterol O-acyltransferase 1 (SOAT1) and its role in immune regulation remain unclear. This study aimed to elucidate the mechanism involved and evaluate the potential of SOAT1 as a therapeutic target. APPROACH AND RESULTS: We explored the role of SOAT1 using genetical and pharmaceutical inhibition in cell lines, patient-derived organoids, and mouse models. Co-culture systems, flow cytometry, and immunohistochemistry were employed to assess tumor-immune interactions. Multi-omics were performed to elucidate the underlying molecular mechanisms. The efficacy of inhibiting SOAT1 alone and in combination with anti-PD1 therapy in vivo was tested. SOAT1 was significantly upregulated in HCC tumors and was associated with increased tumorigenicity and immune-evasive characteristics. SOAT1 deficiency disrupted lipid homeostasis, leading to the accumulation of saturated fatty acids, reactive oxygen species, and endoplasmic reticulum stress, followed by NF-κB activation. This signaling triggered the production of pro-inflammatory cytokines, adhesion molecules, and the recruitment of CD11c + antigen-presenting cells and cytotoxic CD8 + T cells into tumors. Moreover, SOAT1 knockout reduced tumor burden, and the combination of SOAT1 inhibition with PD-1 blockade exhibited synergistic antitumor effects. CONCLUSIONS: SOAT1 functions as both a metabolic vulnerability and an immune regulator in HCC. Its inhibition disrupts tumor-promoting metabolic processes while enhancing immune activation, presenting it as a promising therapeutic target. Combining SOAT1 inhibition with PD-1 blockade holds potential for improving outcomes in HCC immunotherapy.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ma H, Zhang VX, Tsui YM, et al. Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma. Hepatology. 2025. PMID: 41066331. doi:10.1097/HEP.0000000000001561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。